| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | MERCK & CO., INC. CMN | Jun 16, 2026 | |
| Buy | MERCK & CO., INC. CMN | Jun 2, 2026 | |
| Buy | MERCK & CO INC CMN | May 21, 2026 | |
| Buy | MERRELL TECHNOLOGY INC. CMN | Apr 15, 2026 | |
| Buy | MERKEL TECHNOLOGY INC CMN | Apr 15, 2026 | |
| Buy | MERCK & TECHNOLOGIES INC. CM | Apr 15, 2026 | |
| Buy | MERCK & CO INC CMN | Apr 15, 2026 | |
| Buy | MARVELL TECHNOLOGY INC CMN | Apr 15, 2026 | |
| Buy | MERCK TECHNOLOGIES INC CMN | Apr 15, 2026 | |
| Buy | MARVELL TECHNOLOGY INC CMN | Apr 15, 2026 |
This page tracks congressional stock trading activity in Merck & Co., Inc. (MRK) in the Healthcare sector. Disclosed Capitol has indexed 509 disclosed congressional trades involving MRK. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of July 2026 — Disclosed Capitol has tracked 509 disclosed congressional trades in Merck & Co., Inc. (MRK) — 229:163 sell-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jun 16, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Jun 2, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| May 21, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 15, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 15, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 15, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 15, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Apr 15, 2026 | Ro Khanna | D | Buy | $15,001 - $50,000 |
| Apr 15, 2026 | Ro Khanna | D | Buy | $15,001 - $50,000 |
| Apr 15, 2026 | Ro Khanna | D | Buy | $1,001 - $15,000 |
Across the 509 disclosed congressional trades in Merck & Co., Inc. (MRK), members of Congress have reported 163 buys and 229 sells. The average 30-day alpha vs. the S&P 500 is -0.60%.
For fiscal year 2025, Merck & Co., Inc. reported revenue of $65.01B and net income of $18.25B, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $16.61B, net income -$1.33B.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.